News & Updates

An intranasally administered recombinant human erythropoietin without erythropoietic activity and shorter plasma half-life (neuroEPO) restores cognitive function or delays progression in most patients with mild-to-moderate Alzheimer’s disease, results of the phase II/III double-blind, placebo-controlled ATHENEA trial have shown.

In the treatment of patients with acute ischaemic stroke, treatment with exenatide does not appear to have any beneficial effect on neurological function at 7 days but is safe and substantially decreases the frequency of hyperglycaemic events, without leading to hypoglycaemia, according to the results of the phase II TEXAIS trial.

A double-blind, sham-controlled study by researchers from the Hong Kong Polytechnic University shows that cathodal transcranial direct current stimulation (tDCS) of the left dorsolateral prefrontal cortex (dlPFC) paired with cognitive remediation is a feasible and effective treatment for improving social functioning and information processing in adolescents and young adults with autism spectrum disorder (ASD) who have average to borderline IQ.